Ex vivo RSA and pfkelch13 targeted-amplicon deep sequencing reveal parasites susceptibility to artemisinin in Senegal, 2017
Yade M, Dièye B, Coppée R, Mbaye A, Diallo M, Diongue K, Bailly J, Mama A, Fall A, Thiaw A, Ndiaye I, Ndiaye T, Gaye A, Tine A, Diédhiou Y, Mbaye A, Doderer-Lang C, Garba M, Bei A, Ménard D, Ndiaye D. Ex vivo RSA and pfkelch13 targeted-amplicon deep sequencing reveal parasites susceptibility to artemisinin in Senegal, 2017. Malaria Journal 2023, 22: 167. PMID: 37237307, PMCID: PMC10223908, DOI: 10.1186/s12936-023-04588-1.Peer-Reviewed Original ResearchConceptsRing-stage survival assayART resistancePlasmodium falciparum isolatesMost malaria deathsLong-term useCurative treatmentCombination therapyMalaria deathsMinor variantsFalciparum isolatesPfkelch13 geneSurvival assaysParasite susceptibilityResultsAll samplesPfKelch13Spread of parasitesSaharan AfricaExMain determinantsIsolatesTherapySusceptibilityDeep sequencing approachIdentification of an in vitro artemisinin-resistant Plasmodium falciparum kelch13 R515K mutant parasite in Senegal
Sene S, Pouye M, Martins R, Diallo F, Mangou K, Bei A, Barry A, Faye O, Ndiaye O, Faye O, Sall A, Lopez-Rubio J, Mbengue A. Identification of an in vitro artemisinin-resistant Plasmodium falciparum kelch13 R515K mutant parasite in Senegal. Frontiers In Parasitology 2023, 2: 1076759. DOI: 10.3389/fpara.2023.1076759.Peer-Reviewed Original ResearchPlasmodium falciparum clinical isolatesRing-stage survival assayArtesunate-amodiaquine treatmentPlasmodium falciparum malaria parasitesSentinel surveillance systemFalciparum malaria parasitesK mutationDifferent healthcare centersWorldwide malaria burdenPersistent feverAntimalarial treatmentMalaria-infected blood samplesMalaria casesMalaria burdenIndex caseBlood samplesHealthcare centersClinical isolatesMalaria parasitesSurvival assaysMutant parasitesSurveillance systemFunctional significanceTreatmentParasites